Tscan Therapeutics Inc

Price Chart

Risk-Adjusted Performance

Tscan Therapeutics Inc (TCRX) Price Performance

Tscan Therapeutics Inc (TCRX) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $1.03, down 0.96% from the previous close.

Over the past year, TCRX has traded between a low of $0.90 and a high of $2.52. The stock has lost 28.7% over this period. It is currently 59.1% below its 52-week high.

Tscan Therapeutics Inc has a market capitalization of $59.18M.

About Tscan Therapeutics Inc

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.